Compare EYE & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EYE | LMAT |
|---|---|---|
| Founded | 1990 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2017 | 2006 |
| Metric | EYE | LMAT |
|---|---|---|
| Price | $20.77 | $98.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 5 |
| Target Price | $31.22 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 1.8M | 278.7K |
| Earning Date | 05-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | ★ 202.78 | 30.57 |
| EPS | 0.38 | ★ 0.68 |
| Revenue | ★ $1,987,488,000.00 | $249,602,000.00 |
| Revenue This Year | $5.56 | $14.21 |
| Revenue Next Year | $6.58 | $8.88 |
| P/E Ratio | ★ $52.42 | $140.57 |
| Revenue Growth | 9.00 | ★ 13.53 |
| 52 Week Low | $14.75 | $79.01 |
| 52 Week High | $30.02 | $118.01 |
| Indicator | EYE | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 48.08 |
| Support Level | $18.98 | $95.47 |
| Resistance Level | $20.43 | $114.38 |
| Average True Range (ATR) | 0.86 | 3.40 |
| MACD | -0.01 | -0.56 |
| Stochastic Oscillator | 56.89 | 28.12 |
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.